We are presenting a poster at the ESMO Breast Cancer Annual Congress (#ESMOBreast23) from 11-13 May in Berlin. The poster demonstrates that the Digistain Prognostic Score showed high accuracy and predictive performance, and stratified patients with early breast cancer into low or high risk. The low cost, rapidity and accessibility of Digistain’s technology approach has potential as an alternative or addition to existing prognostic tools across real-life clinical practice, including under-resourced settings.
Digistain – Health Tech Challengers 2023 Finalist
We are the finalists of Health Tech Challengers 2023. Join us at the event
